Physician profile
Mark J Bruder
NPI 1609864180
$5,812.25
in general payments reported to CMS, 2019-2025
25 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,007 · 2022: $1,282 · 2023: $1,356 · 2024: $1,121 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,496 · Education: $26.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,496.44 |
| Education | $26.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,633.09 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,115.95 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $523.01 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $473.82 | 2021-2025 | Dupixent |
| Amgen INC. | $377.77 | 2021-2025 | Tezspire |
| Optinose US, INC. | $256.77 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $240.10 | 2021-2025 | |
| Alk-Abello, INC | $176.94 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.02 | 2021-2024 | Takhzyro, Eohilia, Glassia |
| Csl Behring | $133.36 | 2021-2024 | Hizentra |
| Abbvie INC. | $131.41 | 2021-2023 | |
| Genentech USA, INC. | $122.93 | 2021-2025 | Xolair |
| Octapharma USA, INC. | $63.48 | 2023-2024 | Cutaquig |
| Biocryst US Sales Co., LLC | $62.22 | 2022 | |
| Grifols USA, LLC | $62.02 | 2022-2025 | Xembify, Prolastin-C Liquid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $58.16 | 2021-2024 | Auvi-Q |
| Blueprint Medicines Corporation | $55.72 | 2023-2025 | Ayvakit |
| Pfizer INC. | $41.27 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $31.15 | 2022 | |
| Pharming Healthcare, INC. | $19.26 | 2024 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $17.58 | 2021 | |
| Incyte Corporation | $16.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.08 | 2022 | |
| Merck Sharp & Dohme LLC | $13.33 | 2021 | |
| Organon LLC | $12.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bruder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.